Leerink Swann Reiterates Outperform Rating for VIVUS (VVUS)
VIVUS (NASDAQ:VVUS)‘s stock had its “outperform” rating restated by stock analysts at Leerink Swann in a report issued on Friday, Stock Ratings News reports. They currently have a $20.00 price target on the stock. Leerink Swann’s price objective suggests a potential upside of 93.99% from the company’s current price.
VIVUS (NASDAQ:VVUS) traded up 7.42% on Friday, hitting $11.075. 2,927,786 shares of the company’s stock traded hands. VIVUS has a 52-week low of $9.11 and a 52-week high of $23.59. The stock has a 50-day moving average of $10.80 and a 200-day moving average of $12.51. The company’s market cap is $1.117 billion.
VIVUS (NASDAQ:VVUS) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.44) by $0.11. The company had revenue of $5.53 million for the quarter, compared to the consensus estimate of $12.76 million. During the same quarter last year, the company posted ($0.24) earnings per share. Analysts expect that VIVUS will post $-1.97 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cowen and Company upgraded shares of VIVUS from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, October 3rd. They now have a $19.00 price target on the stock, up previously from $13.50. Separately, analysts at Bank of America Corp. reiterated a “buy” rating on shares of VIVUS in a research note to investors on Wednesday, October 2nd. They now have a $17.00 price target on the stock. Finally, analysts at Piper Jaffray Cos. cut their price target on shares of VIVUS from $20.00 to $14.00 in a research note to investors on Thursday, September 12th. They now have a “sell” rating on the stock. Four research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $15.09.
VIVUS, Inc is a biopharmaceutical company. It commercializes and develops therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.